



RICHARD E. JENKINS  
JEFFREY L. WILSON  
ARLES A. TAYLOR, JR.

JENNIFER L. SKORD  
DAVID P. GLOEKLER  
GREGORY A. HUNT  
JOHN A. LAMERDIN, PH.D. (PATENT AGENT)

JENKINS & WILSON, P.A.

PATENT ATTORNEYS  
SUITE 1400 UNIVERSITY TOWER  
3100 TOWER BOULEVARD  
DURHAM, NORTH CAROLINA 27707

TELEPHONE (919) 493-8000  
FACSIMILE (919) 419-0383

WEBSITE  
JENKINSANDWILSON.COM

09/555-349  
12/16/2000

RALEIGH OFFICE

NCSU CENTENNIAL CAMPUS  
VENTURE II SUITE 400  
920 MAIN CAMPUS DRIVE  
RALEIGH, NORTH CAROLINA 27606

TELEPHONE (919) 424-3710  
FACSIMILE (919) 424-3711

December 11, 2000

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. on 12-11-00

Arles A. Taylor, Jr.  
Arles A. Taylor, Jr.  
Date of Signature 12-11-00

Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Patent Application Serial No. 09/555,349 for ANTIBODY PRODUCTION  
METHODS RELATED TO DISRUPTION OF PERIPHERAL TOLERANCE  
IN B LYMPHOCYTES  
Our File No. 180/95 PCT/US

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:

1. Information Disclosure Statement (2 pages);
2. Forms PTO/SB/08A and PTO/SB/08B (in duplicate);
3. Copies of cited references (9 references);
4. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

Respectfully submitted,

JENKINS & WILSON, P.A.

Arles A. Taylor, Jr.

Arles A. Taylor, Jr.  
Registration No. 39,395

AAT/ajm

Enclosures



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on 12-11-00  
*Cheryl Ma*  
Amy J. Martin  
Date of Signature 12-11-00

DEC 15 2000  
PATENT  
TECH CENTER 1000/231  
12-20-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: T. F. Tedder

**Serial No.: 09/555,349**

Group Art Unit:

Filed: May 26, 2000

Docket No.: 180/95 PCT/US

For: ANTIBODY PRODUCTION METHODS RELATED TO DISRUPTION OF PERIPHERAL TOLERANCE IN B LYMPHOCYTES

\*\*\*\*\*

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicant's undersigned attorney brings to the attention of the Patent and Trademark Office the following references. Forms PTO/SB/08A and PTO/SB/08B are attached hereto. Copies of the references are also attached. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited. A copy of the PCT International Search Report from the underlying PCT International Application is also enclosed.

U.S. Patent No. 5,675,063 to Knight et al. discloses immortalized rabbit hybridoma fusion partner.

U.S. Patent No. 5,223,410 to Gargan et al. discloses a method for production of antibodies utilizing an antigen-free animal.

Publication by Bohlen et al. entitled "Cytolysis of Leukemic B-Cells by T-Cells Activated via Two Bispecific Antibodies", Cancer Research, pp. 4310-4314 (September 15, 1993).

Publication by Burnett et al. entitled "Human Monoclonal Antibodies to Defined Antigens", Human Hybridomas and Mab, Plenum Press, pp. 113-133 (1985).



Publication by Brink et al. entitled "Immunoglobulin M and D Antigen Receptors are Both Capable of Mediating B Lymphocyte Activation, Deletion, to Energy After Interaction with Specific Antigen", J. Exp. Med., pp. 991-1005 (October, 1992).

Publication by Sato et al. entitled "CD19 Regulates B Lymphocytes Signaling Thresholds Critical for the Development of B-1 Lineage Cells and Autoimmunity", Immunology, Vol. 157, pp. 4371-4378 (1996).

Publication by Zhou et al. entitled "Tissue-Specific Expression of the Human CD19 Gene in Transgenic Mice Inhibits Antigen-Independent B-Lymphocyte Development", Molecular and Cellular Biology, Vol. 14, No. 6, pp. 3884-3894 (June, 1994).

Publication by Tedder et al. entitled "The CD19-CD21 Complex Regulates Signal Review Transduction Thresholds Governing Humoral Immunity and Autoimmunity", Immunity, Vol. 6, pp. 107-118 (February, 1997).

Early passage of the subject application to issue is earnestly solicited.

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any deficiencies of payment associated with the filing of this Information Disclosure Statement to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.

Date: 12/11/2000

By:

Arles A. Taylor, Jr.  
Arles A. Taylor, Jr.  
Registration No. 39,395

Suite 1400 University Tower  
3100 Tower Boulevard  
Durham, North Carolina 27707  
Telephone: (919) 493-8000  
Facsimile: (919) 419-0383

180/95 PCT/US AAT/ajm

Enclosures